Focus: Spruce Biosciences is a public biotech company focused on treatments for HPA axis disorders, primarily congenital adrenal hyperplasia and polycystic ovary syndrome. The company is early-stage with minimal commercial revenue and an entirely R&D-focused portfolio.
Profile data last refreshed 15h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Spruce Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for Spruce Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Spruce Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Spruce Biosciences appoints two commercial executives By Investing.com - Investing.com Australia
Spruce Biosciences appoints two commercial executives By Investing.com Investing.com Australia
Spruce Biosciences Expands Leadership Team - Contract Pharma
Spruce Biosciences Expands Leadership Team Contract Pharma
Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations - BioSpace
Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations BioSpace
Denali approval revives surrogate-endpoint path in neuronal MPS - BioCentury
Denali approval revives surrogate-endpoint path in neuronal MPS BioCentury
Spruce Biosciences to end collaboration agreement with Kaken Pharmaceutical - Investing.com
Spruce Biosciences to end collaboration agreement with Kaken Pharmaceutical Investing.com
Spruce Biosciences (Nasdaq: SPRB) cuts 2025 loss, exits Kaken pact to focus TA-ERT - Stock Titan
Spruce Biosciences (Nasdaq: SPRB) cuts 2025 loss, exits Kaken pact to focus TA-ERT Stock Titan
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo